Do analysts recommend GMTX or PHAT?

Phathom Pharmaceuticals has a consensus target price of $24.50, suggesting a potential upside of 103.15%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Phathom Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Phathom Pharmaceuticals (PHAT) Competitors

$12.06 +0.51 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$11.77 -0.29 (-2.40%)

As of 07:35 PM Eastern

Compare

PHAT vs. ARQT, ALMS, ADPT, GMTX, and IDYA

Should you buy Phathom Pharmaceuticals stock or one of its competitors? MarketBeat compares Phathom Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phathom Pharmaceuticals include Arcutis Biotherapeutics (ARQT), Alumis (ALMS), Adaptive Biotechnologies (ADPT), Gemini Therapeutics (GMTX), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.

How does Phathom Pharmaceuticals compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Arcutis Biotherapeutics currently has a consensus price target of $34.00, indicating a potential upside of 19.30%. Phathom Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 103.15%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 0 mentions for Phathom Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.50 beat Phathom Pharmaceuticals' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Positive
Phathom Pharmaceuticals	Neutral

Arcutis Biotherapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	9.48	-$16.14M	-$0.03	N/A
Phathom Pharmaceuticals	$175.11M	5.49	-$221.25M	-$2.12	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Summary

Arcutis Biotherapeutics beats Phathom Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Alumis?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Phathom Pharmaceuticals currently has a consensus price target of $24.50, suggesting a potential upside of 103.15%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 35.51%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Phathom Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Alumis has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market.

In the previous week, Alumis had 4 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Alumis and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.00 equaled Alumis'average media sentiment score.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Alumis	Neutral

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Alumis' net margin of -2,825.70%. Phathom Pharmaceuticals' return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Alumis	-2,825.70%	-88.79%	-70.72%

Phathom Pharmaceuticals has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.49	-$221.25M	-$2.12	N/A
Alumis	$24.05M	157.65	-$243.32M	-$1.98	N/A

Summary

Phathom Pharmaceuticals beats Alumis on 9 of the 14 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Adaptive Biotechnologies?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Phathom Pharmaceuticals has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market.

Adaptive Biotechnologies has higher revenue and earnings than Phathom Pharmaceuticals. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.49	-$221.25M	-$2.12	N/A
Adaptive Biotechnologies	$276.98M	11.65	-$59.50M	-$0.33	N/A

Adaptive Biotechnologies has a net margin of -16.82% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 14 mentions for Adaptive Biotechnologies and 0 mentions for Phathom Pharmaceuticals. Adaptive Biotechnologies' average media sentiment score of 0.39 beat Phathom Pharmaceuticals' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Adaptive Biotechnologies	Neutral

Phathom Pharmaceuticals currently has a consensus price target of $24.50, suggesting a potential upside of 103.15%. Adaptive Biotechnologies has a consensus price target of $20.50, suggesting a potential upside of 1.69%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Adaptive Biotechnologies beats Phathom Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Gemini Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Phathom Pharmaceuticals	$175.11M	5.49	-$221.25M	-$2.12	N/A

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Phathom Pharmaceuticals has a consensus target price of $24.50, suggesting a potential upside of 103.15%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Gemini Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

In the previous week, Gemini Therapeutics' average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Phathom Pharmaceuticals	Neutral

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Gemini Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to IDEAYA Biosciences?

Phathom Pharmaceuticals (NASDAQ:PHAT) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Phathom Pharmaceuticals presently has a consensus price target of $24.50, suggesting a potential upside of 103.15%. IDEAYA Biosciences has a consensus price target of $50.25, suggesting a potential upside of 32.38%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

IDEAYA Biosciences has higher revenue and earnings than Phathom Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.49	-$221.25M	-$2.12	N/A
IDEAYA Biosciences	$225.27M	14.81	-$113.70M	-$1.60	N/A

In the previous week, IDEAYA Biosciences had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 2 mentions for IDEAYA Biosciences and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.00 beat IDEAYA Biosciences' score of -0.67 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
IDEAYA Biosciences	Negative

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phathom Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

IDEAYA Biosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Summary

Phathom Pharmaceuticals and IDEAYA Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$921.18M	$3.76B	$6.90B	$12.46B
Dividend Yield	N/A	2.16%	2.67%	6.49%
P/E Ratio	N/A	21.67	27.20	24.27
Price / Sales	5.49	343.24	593.79	118.30
Price / Cash	N/A	147.73	49.34	57.41
Price / Book	-1.96	8.47	10.83	6.38
Net Income	-$221.25M	$23.73M	$3.56B	$331.30M
7 Day Performance	14.53%	1.50%	0.81%	-1.84%
1 Month Performance	20.60%	12.00%	5.61%	0.85%
1 Year Performance	33.70%	62.03%	32.58%	22.18%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	1.5961 of 5 stars	$12.06 +4.4%	$24.50 +103.2%	+33.4%	$921.18M	$175.11M	N/A	110
ARQT Arcutis Biotherapeutics	3.0021 of 5 stars	$26.76 -0.9%	$34.00 +27.1%	+106.6%	$3.38B	$415.62M	N/A	150	News Coverage
ALMS Alumis	2.6088 of 5 stars	$27.14 +2.8%	$40.30 +48.5%	+784.3%	$3.37B	$8.40M	N/A	N/A	Insider Trade
ADPT Adaptive Biotechnologies	2.5918 of 5 stars	$21.40 +2.1%	$20.50 -4.2%	+77.3%	$3.35B	$276.98M	N/A	790	Trending News Insider Trade Gap Down
GMTX Gemini Therapeutics	N/A	$74.78 +6.6%	N/A	+39.3%	$3.24B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. ARQT, ALMS, ADPT, GMTX, and IDYA

How does Phathom Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does Phathom Pharmaceuticals compare to Alumis?

Summary

How does Phathom Pharmaceuticals compare to Adaptive Biotechnologies?

Summary

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. ARQT, ALMS, ADPT, GMTX, and IDYA

How does Phathom Pharmaceuticals compare to Arcutis Biotherapeutics?

Do analysts rate ARQT or PHAT?

Does the media prefer ARQT or PHAT?

Which has more volatility and risk, ARQT or PHAT?

Do insiders and institutionals believe in ARQT or PHAT?

Which has preferable earnings & valuation, ARQT or PHAT?

Is ARQT or PHAT more profitable?

Summary

How does Phathom Pharmaceuticals compare to Alumis?

Do analysts rate PHAT or ALMS?

Which has more risk and volatility, PHAT or ALMS?

Does the media refer more to PHAT or ALMS?

Do insiders & institutionals believe in PHAT or ALMS?

Is PHAT or ALMS more profitable?

Which has higher earnings & valuation, PHAT or ALMS?

Summary

How does Phathom Pharmaceuticals compare to Adaptive Biotechnologies?

Which has more risk and volatility, PHAT or ADPT?

Which has higher earnings & valuation, PHAT or ADPT?

Is PHAT or ADPT more profitable?

Do insiders & institutionals believe in PHAT or ADPT?

Does the media refer more to PHAT or ADPT?

Do analysts rate PHAT or ADPT?

Summary

How does Phathom Pharmaceuticals compare to Gemini Therapeutics?

Which has preferable earnings and valuation, GMTX or PHAT?

Which has more volatility & risk, GMTX or PHAT?

Do analysts recommend GMTX or PHAT?

Is GMTX or PHAT more profitable?

Does the media favor GMTX or PHAT?

Do institutionals & insiders hold more shares of GMTX or PHAT?

Summary

How does Phathom Pharmaceuticals compare to IDEAYA Biosciences?

Do analysts prefer PHAT or IDYA?

Which has better valuation & earnings, PHAT or IDYA?

Does the media refer more to PHAT or IDYA?

Do insiders & institutionals hold more shares of PHAT or IDYA?

Which has more risk & volatility, PHAT or IDYA?

Is PHAT or IDYA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools